Expert NetworkExpert InterviewMRK

Slingshot members are talking to an expert! The topic is:

Looking at the FDA approval of Enflonsia (clesrovimab) and Beyfortus (nirsevimab) as a Monoclonal Antibody Approach for Prevention of RSV Infections in Infants

Executed on:Jun 27, 2025 4:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: UCLA Medical Center
  • General Pediatrician in the Division of General Pediatrics at UCLA
  • Manages 100+ patients per year with RSV

Interview Goal

Discussing the RSV prevention landscape, including vaccines and monoclonal antibodies from Merck and AstraZeneca/Sanofi

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.